|Articles|December 8, 2022
- Pharmaceutical Executive-12-01-2022
- Volume 42
- Issue 12
Pharmaceutical Executive, December 2022 Issue (PDF)
Advertisement
Articles in this issue
over 3 years ago
2023 Pipeline Report: Testing the Limitsover 3 years ago
Business and Passionover 3 years ago
Aligning Trust and Transparency in Brand Messagingover 3 years ago
Pharma Needs to Look Internally for New Leadershipover 3 years ago
Seeking Concrete Solutions to Europe’s Supply Problemsover 3 years ago
Pandemic and Politics Shaped Pharma and FDA in 2022over 3 years ago
Medical Affairs Uptickover 3 years ago
Virtual Medical Affairs Audits: A Viable AlternativeAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5